agree.The market cap is $60m, while cash is $30m (after debt)....

agree.The market cap is $60m, while cash is $30m (after debt). It’s hard to image theremaining asset of the company is worth only $30m.
https://starpharma.com/technology

It’s far better to buy a wonderfulcompany at fair price, than a fair company at wonderful price.
time will tell if SPL is a wonderfulcompany. Its technology seems substantially value-adding to improvepharmaceutical product performance etc. we have already seen a fewcommercialisation of the technology.

if it can utilise it’s technology insubstantial, substantive application , like the way MRNA changes vaccines. Itwould be wonderful.